The Charles Schwab Corporation: 2Q26 Review: EPS Beat Guidance Raise; L/S Biz Remains Key Topic of Debate

Research evidence excerpt

The Charles Schwab Corporation: 2Q26 Review: EPS Beat Guidance Raise; L/S Biz Remains Key Topic of Debate

Barclays | The Charles Schwab Corporation

Valuation Methodology: Our price target of $125 is based on 15x our F27 EPS estimate of $8.36. Our 15x multiple reflects the company's strong

financial position and operating history, and supportive macro environment.

Risks which May Impede the Achievement of the Barclays Research Valuation and Price Target: Key risks include regulatory risk related to

payments for order flow, integration risk related to the TD Ameritrade acquisition, interest rate risk, and macro risk.

Disclaimer:

This publication has been produced by Barclays Research Department in the Investment Bank of Barclays Bank PLC and/or one or more of its affiliates

(collectively and each individually, "Barclays").

It has been prepared for institutional investors and not for retail investors. It has been distributed by one or more Barclays affiliated legal entities listed

below or by an independent and non-affiliated third-party entity (as may be communicated to you by such third-party entity in its communications

with you). It is provided for information purposes only, and Barclays makes no express or implied warranties, and expressly disclaims all warranties of

merchantability or fitness for a particular purpose or use with respect to any data included in this publication. Barclays may provide research to certain

categories of recipients that do not use it for investment purposes, including public and private companies in covered industries, media organisations,

regulators, and academic institutions that use such research for their own internal informational, news gathering, regulatory or academic purposes. To